ArticleChest2017
Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.
Article in Chest, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Significant Predictors of Azithromycin in Population Pharmacokinetic Analysis: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).Thorax · 2025Article
- Epidemiology of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- EMBARCing on a new era for bronchiectasis: a review series for the Seventh World Bronchiectasis Conference.European respiratory review : an official journal of the European Respiratory Society · 2024Article
- The COPD Foundation on Its Twentieth Anniversary.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Risk Factors for Influenza-Induced Exacerbations and Mortality in Non-Cystic Fibrosis Bronchiectasis.Viruses · 2023Article
- Review
- Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis.ERJ open research · 2022Article
- Clinical characteristics of patients with bronchiectasis with nontuberculous mycobacterial disease in Mainland China: a single center cross-sectional study.BMC infectious diseases · 2021Observational
- Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2021Article
- Influence of Comorbidities and Airway Clearance on Mortality and Outcomes of Patients With Severe Bronchiectasis Exacerbations in Taiwan.Frontiers in medicine · 2021Article
- Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Article
- Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach.Frontiers in immunology · 2020Review
- Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration.ERJ open research · 2019Article
- Non-Cystic Fibrosis Bronchiectasis: Microbiology, Clinical Outcomes, and Pharmacotherapy Practices.American journal of respiratory and critical care medicine · 2019Article
- Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?F1000Research · 2019Review
- Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection.Annals of the American Thoracic Society · 2018Article
- Medical management of bronchiectasis.Journal of thoracic disease · 2018Review
- Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat?ERJ open research · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 18 institutions in 1 country.
Funding
Abstract
backgroundNon-cystic fibrosis bronchiectasis ("bronchiectasis") is a chronic inflammatory lung disease often associated with nontuberculous mycobacteria (NTM) infection. Very little data exist to guide bronchiectasis management decisions. We sought to describe patterns of inhaled corticosteroid (ICS) and antibiotic therapy in the United States.
methodsWe invited 2,000 patients through NTM Info & Research (NTMir) to complete an anonymous electronic survey. We separately queried baseline clinical and laboratory data from the US Bronchiectasis and NTM Research Registry (BRR).
resultsAmong 511 NTMir survey responders with bronchiectasis, whose median age was 67 years, 85 (17%) reported asthma and 99 (19%) reported COPD. History of ICS use was reported by 282 (55%), 171 (61%) of whom were treated 1 year or longer, and 150 (53%) were currently taking ICSs. Fewer reported ever taking azithromycin for non-NTM bronchiectasis (203 responders [40%]) or inhaled tobramycin (78 responders [15%]). The median age of 1,912 BRR patients was 69 years; 528 (28%) had asthma and 360 (19%) had COPD. Among 740 patients (42%) without NTM, 314 were taking ICSs at baseline. Among patients without NTM who were taking ICSs, only 178 (57%) had a concurrent diagnosis of COPD or asthma that could explain ICS use. Fewer were taking suppressive macrolides (96 patients [13%]), and of the 70 patients (10%) taking inhaled suppressive antibiotics, 48 (68%) had chronic Pseudomonas aeruginosa infection.
conclusionsICS use was common in two national samples of patients with bronchiectasis, with relatively few patients taking suppressive antibiotic therapies. Further research is needed to clarify the safety and effectiveness of these therapies in patients with bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.